Natixis Advisors LLC boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 4.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 478,579 shares of the company's stock after buying an additional 21,539 shares during the quarter. Natixis Advisors LLC's holdings in Takeda Pharmaceutical were worth $6,336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also bought and sold shares of the company. Public Employees Retirement System of Ohio purchased a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at $601,000. QRG Capital Management Inc. boosted its position in Takeda Pharmaceutical by 16.8% during the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock valued at $4,364,000 after buying an additional 47,490 shares during the period. Verition Fund Management LLC bought a new position in shares of Takeda Pharmaceutical during the third quarter valued at about $1,533,000. HighTower Advisors LLC increased its holdings in shares of Takeda Pharmaceutical by 199.5% in the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company's stock worth $1,744,000 after buying an additional 81,653 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $957,000. 9.17% of the stock is currently owned by institutional investors.
Takeda Pharmaceutical Trading Up 0.8 %
TAK traded up $0.12 on Tuesday, hitting $15.13. 202,300 shares of the company were exchanged, compared to its average volume of 1,798,135. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.31. The firm has a fifty day simple moving average of $14.00 and a two-hundred day simple moving average of $13.91. The stock has a market capitalization of $48.13 billion, a PE ratio of 37.81, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Articles
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
